logo

Rxi Pharmaceuticals Corp. (RXII)



Trade RXII now with
  Date
  Headline
11/14/2018 7:13:14 AM RXi Pharmaceuticals Q3 Net Loss $1.5 Mln Vs Loss $2.5 Mln Last Year
10/3/2018 4:36:26 PM RXi Pharmaceuticals Closes $15 Mln Underwritten Public Offering
10/1/2018 6:12:44 AM RXi Pharma Announces Pricing Of Underwritten Public Offering Of 21.43 Mln Units At $0.70/Unit
9/26/2018 8:04:35 AM RXi Pharma To Present New Data From Its Immuno-Oncology Program Using Sd-rxRNA Therapeutic Compounds
8/15/2018 9:26:15 AM RXi Pharma And Karolinska Institutet Enter Into Collaboration To Develop Sd-rxRNA Compounds
8/14/2018 9:18:32 AM RXi Pharma Q2 Net Loss $1.9 Mln Or $0.46/shr Vs. Loss $2.5 Mln Or $1.12/shr Prior Year
8/2/2018 9:27:10 AM RXi Secures Patents For Sd-rxRNA Technology Strengthening Intellectual Property Estate In Europe And Japan
8/1/2018 9:26:21 AM RXi Pharma Unveils Positive Results From Phase 1/2 Trial With RXI-109 For Retinal Scarring
5/11/2018 7:06:52 AM RXi Enters Research Collaboration With Iovance Biotherapeutics
5/10/2018 7:08:15 AM RXi Pharmaceuticals Q1 Loss Per Share $0.90; Revenues $23K
4/11/2018 1:25:04 PM RXi Pharmaceuticals Announces Closing Of $4.9 Mln Registered Direct Offering
4/9/2018 2:09:31 PM RXi Pharmaceuticals Announces $4.9 Mln Registered Direct Offering
  
 
>